medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-11-33-37medsovet-666Research ArticleКАРДИОЛОГИЯCARDIOLOGYАторвастатин во вторичной профилактике сердечнососудистых заболеванийAtorvastatin in the secondary prevention of cardiovascular diseasesВаулинН. А.VaulinN. A.noemail@neicon.ruГородская клиническая больница №29 им. Н.Э. БауманаРоссияCity Hospital №29 named after N.E. BaumanRussian Federation2014301220140113337Copyright © Ваулин Н.А., 20142014Ваулин Н.А.Vaulin N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/666

Клинические проявления атеросклеротического процесса лидируют среди причин смертности, заболеваемости и инвалидизации взрослого населения экономически развитых стран мира. В ходе многолетнего изучения была однозначно доказана связь между риском развития сердечно-сосудистых осложнений и повышенным уровнем холестерина крови. Многочисленные международные эпидемиологические исследования, такие как, например, Фрэмингемское исследование [1] и INTERHEART [2], подводят под это утверждение серьезную доказательную базу. Более того, рандомизированные клинические исследования с применением гиполипидемических вмешательств последних 10-15 лет свидетельствуют о том, что более активное снижение холестерина сопровождается большим снижением риска развития осложнений.

Clinical manifestations of the atherosclerotic process are leading causes of mortality, morbidity and disability in the adult population of the developed countries all over the world. Many years of research have established a clear relationship between the risk of cardiovascular disease and high cholesterol level. Numerous global epidemiological studies, such as, for example, the Framingham Heart Study [1] and INTERHEART [2], provided solid evidence confirming that statement. Moreover, randomized clinical trials of lipid-lowering interventions over the past 10-15 years demonstrate that greater cholesterol reduction is associated with a significant decrease in the risk of complications.

сердечно-сосудистые заболеванияпрофилактикастатиныаторвастатинcardiovascular diseasepreventionstatinsatorvastatinReferencesAnderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987, 257:2176-2180.Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987, 257:2176-2180.INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet, 364, Issue 9438: 937-952.INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet, 364, Issue 9438: 937-952.Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin, 2011, 27(8): 1551-1562.Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin, 2011, 27(8): 1551-1562.Jones PH, Davidson MH, Stein EA et al. For the STELLAR Study Group. Comparison of the efficacy and safety of rosuvas-tatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol., 2003, 92: 152-160.Jones PH, Davidson MH, Stein EA et al. For the STELLAR Study Group. Comparison of the efficacy and safety of rosuvas-tatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol., 2003, 92: 152-160.Nofer JR. Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study. Curr OpinLipidol. 2012, 23(3): 260-2.Nofer JR. Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study. Curr OpinLipidol. 2012, 23(3): 260-2.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344: 1383-1389.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344: 1383-1389.Sacks FM, Pfeffer MA, Moye LA et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996, 355: 10011009.Sacks FM, Pfeffer MA, Moye LA et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996, 355: 10011009.Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998, 339: 1349-1357.Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998, 339: 1349-1357.White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000, 343: 317-326.White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000, 343: 317-326.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet. 2002, 360: 7-22.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet. 2002, 360: 7-22.Schwartz GC, Olsson AG, Ezekowitz MD et al. For the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA. 2001, 285: 1711-1718.Schwartz GC, Olsson AG, Ezekowitz MD et al. For the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA. 2001, 285: 1711-1718.Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG.Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG.Curr Med Res Opin. 2002, 18(4): 220-8.Curr Med Res Opin. 2002, 18(4): 220-8.ESC Guidelines for the Management of Dyslipidaemias. European Heart Journal 2011, 32(14): 1769-1818, doi: 10.1093/ eurheartj/ehr 158 & Atherosclerosis, 2011, Jul, 217(1): 3-46, doi: 10.1016/j.atherosclerosis.2011.06.012.ESC Guidelines for the Management of Dyslipidaemias. European Heart Journal 2011, 32(14): 1769-1818, doi: 10.1093/ eurheartj/ehr 158 & Atherosclerosis, 2011, Jul, 217(1): 3-46, doi: 10.1016/j.atherosclerosis.2011.06.012.Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007 (6), 3.Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007 (6), 3.Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998, 1, 81(5): 582-7.Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998, 1, 81(5): 582-7.A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.JAMA. 2004, 15, 292(11): 1307-16.A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.JAMA. 2004, 15, 292(11): 1307-16.Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med, 2002, 14, 346 (7): 539-540.Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med, 2002, 14, 346 (7): 539-540.Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol, 2009, 104 (11): 1603-1605. Epub 2009 Oct 14.Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol, 2009, 104 (11): 1603-1605. Epub 2009 Oct 14.GALAXY lipid studies 1. Lablanche J-M et al. Atherosclerosis Supplements. 2006, 7(3): 578, Abs.GALAXY lipid studies 1. Lablanche J-M et al. Atherosclerosis Supplements. 2006, 7(3): 578, Abs.

The authors declare that there are no conflicts of interest present.